What:
Bowtie will fully sponsor 1,300 of its selected life insurance customers within the age group of 40 – 60 to conduct a Take2 Prophecy™ Test for Nasopharyngeal Cancer (NPC).
Why:
With NPC being one of the five most common cancers among men aged 45 to 64, statistics from the Hong Kong Hospital Authority highlight that 70 – 80% of the city’s NPC patients were diagnosed at stages 3 & 4, providing insight into the lack of effective NPC screening solutions.
How:
- Adopting the Next-generation Sequencing (NGS) technology in NPC screening, Take2 allows the early detection of NPC.
- It enables patients to be diagnosed at earlier stages (stages 1 & 2), increasing survival rate by nearly 30% compared to diagnosis at later stages.
- So, SCOR, Bowtie, and Take2 aim to help the public learn about the potential risks of NPC, in order to conduct early NPC detection.
- Selected Bowtie insureds can enjoy a Take2 Prophecy™ NPC detection Test at Bowtie’s medical clinic, Bowtie & JP Health, for the service fee only.
- The test result will not affect their current coverage, underwriting results, or claim eligibility with Bowtie.
- For positive test results, a free follow-up medical consultation will be provided by Bowtie & JP Health.
For application, users can:
• Access the “Health Services” page after logging into their Bowtie account;
• Obtain the QR code for a Take2 Prophecy™ NPC detection, and save the screenshot on their mobile;
• Make an appointment on the Bowtie & JP Health website, or call
• Present the QR code on their visit to Bowtie & JP Health and conduct the test.